Abstract
Computationally designed protein nanoparticles have recently emerged as a promising platform for the development of new vaccines and biologics. For many applications, secretion of designed nanoparticles from eukaryotic cells would be advantageous, but in practice, they often secrete poorly. Here we show that designed hydrophobic interfaces that drive nanoparticle assembly are often predicted to form cryptic transmembrane domains, suggesting that interaction with the membrane insertion machinery could limit efficient secretion. We develop a general computational protocol, the Degreaser, to design away cryptic transmembrane domains without sacrificing protein stability. The retroactive application of the Degreaser to previously designed nanoparticle components and nanoparticles considerably improves secretion, and modular integration of the Degreaser into design pipelines results in new nanoparticles that secrete as robustly as naturally occurring protein assemblies. Both the Degreaser protocol and the nanoparticles we describe may be broadly useful in biotechnological applications.
Introduction
Computationally designed protein nanoparticles are a "holy grail" for modern medicine, offering a programmable platform for vaccines and targeted drug delivery. However, a major bottleneck exists: while these proteins are easy to produce in bacteria, they often fail to secrete efficiently from the eukaryotic cells (such as CHO or HEK293) required for complex human-like modifications like glycosylation.
Researchers discovered that the very feature that makes these nanoparticles assemble—large, hydrophobic interfaces—is also their downfall. When a cell attempts to secrete these proteins, its "quality control" machinery, specifically the Sec translocon, mistakes these hydrophobic patches for transmembrane domains. Instead of being exported, the proteins become trapped in the endoplasmic reticulum membrane, leading to poor yields and clogged cellular pathways. This study introduces a "negative design" approach to ensure proteins avoid these unintended membrane interactions.
Methods
The authors introduced a negative design protocol integrated into the Rosetta macromolecular modeling suite, named The Degreaser. The tool uses a sliding window of 19 amino acids to scan protein sequences and calculate the predicted free energy of membrane insertion ($\Delta G_{ins,pred}$) based on a biological hydrophobicity scale.
By benchmarking 309 known transmembrane and 585 non-transmembrane proteins, the team established a $\Delta G_{ins,pred}$ threshold of +2.7 kcal/mol to distinguish "safe" sequences from "risky" ones. If a segment falls below this threshold, the algorithm iteratively tests minimal mutations, prioritizing those that swap hydrophobic residues for polar ones while ensuring the overall protein structure remains stable and the assembly interface is preserved.
Results
The protocol was validated both retroactively on existing designs and prospectively on new ones. For the nanoparticle component I53_dn5A, the Degreaser improved secretion yield by nearly 100-fold. Similarly, a "degreased" variant of the popular I3-01 nanoparticle showed a 64-fold increase in yield.
In a prospective study involving a new library of 99 "Khmelinskaia-Wang One-Component Assemblies" (KWOCAs), 87% of the designs incorporating the Degreaser secreted successfully, compared to only 63-67% for conventional design methods. The best-designed nanoparticles achieved secretion levels comparable to robust, naturally occurring protein assemblies like ferritin.
Crucially, structural fidelity was maintained. Cryo-EM and Small-Angle X-ray Scattering (SAXS) confirmed that the degreased nanoparticles still assembled into their intended, high-symmetry shapes, such as tetrahedral, octahedral, or icosahedral architectures.
Discussion
The success of The Degreaser highlights that negative design—ensuring a protein doesn't do what you don't want—is as critical for biological utility as positive design. The identified +2.7 kcal/mol threshold provides a concrete metric for future protein engineering.
While highly effective, the current strategy is conservative, often limiting changes to a single mutation. Future work could explore multiple mutations to further boost yields. Additionally, while cryptic transmembrane domains are a major hurdle, other factors like folding kinetics and specific exit signals also influence secretion. Beyond nanoparticles, "degreasing" could be applied to antibodies, enzymes, and other therapeutic proteins to enhance production yields in eukaryotic systems.
Summary updated